SLC2A1 and neoplasm: Administering selective GLUT1 inhibitors such as rapamycin (mTOR-signaling inhibitor), metformin, and a ketogenic diet for reducing tumor glucose uptake and thereby improving CAR T-cell metabolism.Employing CRISPR/Cas9 technology to knock out enzymes implicated in tumor metabolism, such as diacylglycerol kinase